You are hereOctober 28, 2018
What’s the Stem Cells Buzz this Week? - Cyclosporine’s Effect on ECFCs, Reviewing CSC Targeted Therapies, HSPCs as Immunomodulators in Cancer, and the Development of Carcinoma-associated MSCs!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Deleterious Effect of Cyclosporine on Endothelial Colony Forming Cells
The application of immunosuppressive compounds, such as cyclosporine, aims to improve allogeneic stem cell engraftment; however, can this impact stem cell function? Researchers from the group of Jatin Patel (University of Queensland, Australia) assessed the consequence of cyclosporine treatment on hindlimb revascularization via the application of endothelial colony forming cells (ECFC) and mesenchymal stem cells (MSC). Interestingly, the team discovered a deleterious effect of the immunosuppressive agent on the function and survival of ECFCs in vivo. Sim et al. believe that their new findings, published inSTEM CELLS Translational Medicine, will have significant clinical implications for allogeneic stem cell therapies treating ischemic disease.
Reviewing Cancer Stem Cell Targeted Therapies
A new concise review from the lab of Stanton L. Gerson (Case Western Reserve University, Cleveland, Ohio USA) summarizes ongoing preclinical and clinical efforts to therapeutically target cancer stem cells (CSCs), a distinct subpopulation of tumor cells implicated in therapy resistance and metastasis. This STEM CELLS Translational Medicine article from Desai et al. reviews signaling pathways involved in cancer stem cell maintenance and highlights novel approaches, such as epigenetic targeting and immunotherapy, that hold promise for improving patient outcomes.
Hematopoietic Stem and Progenitor cells as Immunomodulators in Cancer
Our next review article from the laboratory of Catherine T. Flores (University of Florida, Gainesville, Florida, USA) highlights studies into a critical role for hematopoietic stem and progenitor cells (HPSCs) as modulators of cancer immunity that could be incorporated into cellular immunotherapy strategies. Writing in STEM CELLS, Wildes et al. discuss both the immunosuppressive role of HSPCs during solid malignancies and the recent studies that uncovered immune‐activating HSPCs and progeny. Sounds like a great read!
Carcinoma‐associated Mesenchymal Stem Cells Arise from Tissue-specific Normal Stroma
Carcinoma‐associated mesenchymal stem cells (CA‐MSCs), critical stromal progenitor cells within the tumor microenvironment, promote tumor cell growth while increasing cancer “stemness” and chemotherapeutic resistance. Recent research from the lab of Lan G. Coffman (University of Pittsburgh, Pittsburgh, PA, USA) applied RNA sequencing of normal omental MSCs and ovarian CA‐MSCs to create a unique predictive algorithm to classify CA‐MSCs. By applying this model, the team definitively demonstrate that ovarian CA‐MSCs arise from tumor-mediated reprogramming of local tissue MSCs, thereby providing powerful insights into the mechanisms underlying cancer specific metastatic niche formation. See STEM CELLS now for a fascinating read.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!